Expression, Function and Trafficking of the Human ABCG2 Multidrug Transporter Containing Mutations in an Unstructured Cytoplasmic Loop
Authors:
- Orsolya MóznerOrsolya Mózner
- Boglárka ZámbóBZBoglárka Zámbó
- Zsuzsa BartosZBZsuzsa Bartos
- Anna GergelyAGAnna Gergely
- Kata Sára SzabóKSKata Sára Szabó
- Bálint JezsóBJBálint Jezsó
- Ágnes TelbiszÁTÁgnes Telbisz
- György VáradyGVGyörgy Várady
- László HomolyaLHLászló Homolya
- Tamás HegedűsTHTamás Hegedűs
- Balázs SarkadiBalázs Sarkadi
Open Access
Abstract
The human ABCG2 multidrug transporter plays a crucial role in the absorption and excretion of xeno- and endobiotics, contributes to cancer drug resistance and the development of gout. In this work, we have analyzed the effects of selected variants, residing in a structurally unresolved cytoplasmic region (a.a. 354–367) of ABCG2 on the function and trafficking of this protein. A cluster of four lysines (K357–360) and the phosphorylation of a threonine (T362) residue in this region have been previously suggested to significantly affect the cellular fate of ABCG2. Here, we report that the naturally occurring K360del variant in human cells increased ABCG2 plasma membrane expression and accelerated cellular trafficking. The variable alanine replacements of the neighboring lysines had no significant effect on transport function, and the apical localization of ABCG2 in polarized cells has not been altered by any of these mutations. Moreover, in contrast to previous reports, we found that the phosphorylation-incompetent T362A, or the phosphorylation-mimicking T362E variants in this loop had no measurable effects on the function or expression of ABCG2. Molecular dynamics simulations indicated an increased mobility of the mutant variants with no major effects on the core structure of the protein. These results may help to decipher the potential role of this unstructured region within this transporter.Keywords
All Related Versions
Funding Information
- National Research, Development and Innovation Office (K 128123, K 127961, K 137610, KDP-2020)
- National Research, Development and Innovation Fund (K 128123, K 127961, K 137610, KDP-2020)
This publication has 40 references indexed in Scilit:
- Common dysfunctional variants in ABCG2 are a major cause of early-onset goutScientific Reports, 2013
- Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistanceBiochemical Pharmacology, 2012
- Synchronization of secretory protein traffic in populations of cellsNature Methods, 2012
- MDAnalysis: A toolkit for the analysis of molecular dynamics simulationsJournal of Computational Chemistry, 2011
- Dynamic vs Static ABCG2 Inhibitors to Sensitize Drug Resistant Cancer CellsPLOS ONE, 2010
- Identification of a urate transporter, ABCG2, with a common functional polymorphism causing goutProceedings of the National Academy of Sciences, 2009
- ABCG2: A perspectiveAdvanced Drug Delivery Reviews, 2009
- Interaction with the 5D3 Monoclonal Antibody Is Regulated by Intramolecular Rearrangements but Not by Covalent Dimer Formation of the Human ABCG2 Multidrug TransporterJournal of Biological Chemistry, 2008
- Combined localization and real-time functional studies using a GFP-tagged ABCG2 multidrug transporterBiochemical and Biophysical Research Communications, 2008
- Modeling of loops in protein structuresProtein Science, 2000